Mesenchymal Stem Cell Therapy for Huntington Disease: A Meta-Analysis

Table 2

The methodological quality of enrolled studies.

First author and publication year	1	2	3				4	5	6	7	8	9	10	Quality score
			Species	Background	Sex	Age
Bayat 2021 [12]	1	1	1	1	1	1	0	1	1	1	1	1	1	12
Yu-Taeger 2019 [16]	1	0	1	1	1	1	0	1	1	1	0	1	1	10
Elbaz 2019 [17]	1	1	1	1	1	0	0	0	1	1	0	1	1	9
Ebrahimi 2018 [18]	1	1	1	1	1	1	0	1	1	1	1	1	1	12
Linares 2016 [19]	1	1	1	1	1	1	1	1	1	1	1	1	1	13
Rossignol 2015 [20]	1	0	1	1	1	1	1	1	1	1	1	1	1	12
Fink 2013 [21]	1	0	1	1	1	1	0	1	1	1	1	1	1	11
Sadan 2012 [22]	1	0	1	1	1	0	0	1	1	1	0	0	1	9
Sadan 2012 [23]	1	1	1	0	0	0	0	0	1	1	0	0	1	6
Moraes 2012 [24]	1	0	1	1	1	1	0	1	1	1	0	0	1	9
Lin 2011 [25]	1	1	1	1	1	1	0	1	1	1	0	1	1	11
Im 2010 [26]	1	0	1	0	0	1	0	1	1	1	1	1	1	9
Edalatmanesh 2010 [27]	1	0	1	1	1	0	0	0	1	1	1	1	1	9
Lee 2009 [28]	1	0	1	1	1	1	0	1	1	1	1	1	1	11
Amin 2008 [29]	1	0	1	1	0	1	0	1	1	1	0	0	1	8

(1) Published in a peer-reviewed journal; (2) randomization was used; (3) detailed animal characteristics were stated ((a) species, (b) background, (c) sex, and (d) age of the animals); (4) blinded assessment of behavioral outcome was used; (5) the specific age at which MSCs were transplanted was stated; (6) the administration route was stated; (7) the number of MSCs was stated; (8) pretreatment behavioral assessment was conducted; (9) potential conflicts of interest were stated; and (10) suitable animal models were used.